Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-217 Phase 2 Study in Moderate to Severe MDD
NCT03000530Phase 2Completed
- Sponsor
- Biogen
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zuranolone in major depressive disorder (MDD) (3 arms), sponsored by Biogen. Primary endpoints: Treatment-emergent Adverse Events, 17-item Hamilton Rating Scale for Depression Total Score at Day 15 and 2 more. Started Dec 2016; status: completed.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03000530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000530.